The UK award for the most innovative new drug has been moved a step closer with the release of a shortlist in the running for this prestigious prize.
The UK Prix Galien, which is held every two years and celebrates innovative new drugs, has shortlisted products that were launched or granted a new indication in the UK between 1 January 2010 and 31 March 2012.
We were pleased to see that pH Associates are already working with our clients on 5 of the top 12 products and hope to see this number growing over the coming months. Our clients are recognising the need for real world data to demonstrate the value of these innovative products in order to drive uptake in clinical practice and improve patient care.
12 medicines have made the shortlist, which will return to the House of Commons on 26 September. These drugs are:
• Amgen’s Xgeva (denosumab) for skeletal-related events in adults with bone metastases from solid tumours
• AstraZeneca’s Brilique (ticagrelor) for atherothrombotic events in adult patients with Acute Coronary Syndromes
• Bayer’s Xarelto (rivaroxaban) for deep vein thrombosis, prevention or recurrent DVT and pulmonary embolism
• BMS’ Yervoy (ipilimumab) for advanced melanoma
• Janssen’s Xeplion (paliperidone palmitate) for schizophrenia
• Janssen’s Zytiga (abiraterone) for metastatic castration resistant prostate cancer
• Janssen’s Incivo (telaprevir) for chronic hepatitis C
• Novartis’ Gilenya (fingolimod) for remitting relapsing multiple sclerosis
• Roche’s Zelboraf (vemurafenib) for BRAF positive melanoma
• Shire Resolor (prucalopride) for chronic constipation in women
• MSD’s Victrelis (boceprevir) for chronic hepatitis C
• Takeda UK’s Mepact (mifamurtide) for osteosarcoma (Nominated for the Orphan Drug Award).
NICE chairman Professor Sir Michael Rawlins leads the Prix Galien’s judging panel. His team also includes experts such as Professor Dame Carol Black, Professor Parveen Kumar, Professor Gordon Duff and the current national cancer director, Professor Sir Michael Richards.